Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial.

@article{Mead2015ResponseTR,
  title={Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial.},
  author={Adam J Mead and Dragana Milojkovic and Steven Knapper and Mamta Garg and Joseph Chacko and Mira H Farquharson and John Ahman Liu Yin and Sahra Ali and Richard E. Clark and Chris Andrews and Meryem Ktiouet Dawson and Claire N Harrison},
  journal={British journal of haematology},
  year={2015},
  volume={170 1},
  pages={29-39}
}
Myelofibrosis is characterized by splenomegaly and debilitating constitutional symptoms that negatively impact patients' quality of life. ROBUST, a UK, open-label, phase II study, evaluated the safety and efficacy of ruxolitinib in patients with myelofibrosis (N = 48), including intermediate-1 risk patients. The primary composite endpoint was the proportion of patients achieving treatment success [≥ 50% reduction in palpable spleen length and/or a ≥ 50% decrease in Myelofibrosis Symptom… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

Similar Papers

Loading similar papers…